These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Industry-sponsored pharmaceutical trials and research ethics boards: are they cloaked in too much secrecy? Ferris LE CMAJ; 2002 May; 166(10):1279-80. PubMed ID: 12041844 [No Abstract] [Full Text] [Related]
4. [Pharmaceutical industry and clinical drug research]. Huttunen MO Duodecim; 2000; 116(24):2813-5. PubMed ID: 12077886 [No Abstract] [Full Text] [Related]
5. [Implementation of new Japanese GCP and the quality of clinical trials--from the standpoint of the pharmaceutical industry]. Ebi O Gan To Kagaku Ryoho; 1997 Oct; 24(13):1883-91. PubMed ID: 9350232 [TBL] [Abstract][Full Text] [Related]
6. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives]. Englev E; Petersen KP Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823 [TBL] [Abstract][Full Text] [Related]
8. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials. Matcham J; Julious S; Pyke S; O'Kelly M; Todd S; Seldrup J; Day S Pharm Stat; 2011; 10(1):70-3. PubMed ID: 20187020 [TBL] [Abstract][Full Text] [Related]
10. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint. Legler UF Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261 [TBL] [Abstract][Full Text] [Related]
11. [The personal data act, clinical trials and data privacy. Rules for treatment of personal data in clinical trials and scientific research projects]. Daasnes C Ugeskr Laeger; 2003 Apr; 165(16):1683-5. PubMed ID: 12756831 [TBL] [Abstract][Full Text] [Related]
12. [Clinical research and pharmaceutical industry. A relationship with advantages and disadvantages]. ten Cate JW; Büller HR Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1572-6. PubMed ID: 10443284 [TBL] [Abstract][Full Text] [Related]
13. [Clinical trials in Norway--completion and reporting are not satisfactory]. Sandaker L; Fjeld B; Reikvam A; Lislevand H; Madsen S Tidsskr Nor Laegeforen; 2004 Nov; 124(22):2888-90. PubMed ID: 15550958 [TBL] [Abstract][Full Text] [Related]
14. Conflict of interest in clinical research: direct payment to the investigators for finding human subjects and health information. Puttagunta PS; Caulfield TA; Griener G Health Law Rev; 2002; 10(2):30-2. PubMed ID: 15739309 [TBL] [Abstract][Full Text] [Related]
16. Industry sponsorship and authorship of clinical trials over 20 years. Buchkowsky SS; Jewesson PJ Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982 [TBL] [Abstract][Full Text] [Related]
17. [Drug development costs are overstated by the industry]. Jeppsson A Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545 [No Abstract] [Full Text] [Related]
18. [Quality assurance in clinical studies: a necessity]. Boll M; Binder J; Siegel A; Grundmann R Z Exp Chir Transplant Kunstliche Organe; 1990; 23(2):65-72. PubMed ID: 2278157 [TBL] [Abstract][Full Text] [Related]
19. Experiences with GCP in the pharmaceutical industry [corrected]. Rämsch KD Methods Find Exp Clin Pharmacol; 1993 May; 15(4):237-40. PubMed ID: 8240533 [TBL] [Abstract][Full Text] [Related]
20. [Pharmaceutical companies as sponsors of clinical trials--advantages and limitations]. Reis LL Rev Port Cardiol; 1992 Apr; 11(4):333-8. PubMed ID: 1632988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]